What's Happening?
4DMedical Limited, a leader in cardiothoracic imaging software, has announced that its CT:VQ imaging technology has received CE Mark certification, allowing for its commercial use across the European Union. This development follows the technology's growing
adoption in the United States, where it is already deployed at major academic medical centers such as Stanford and Cleveland Clinic. CT:VQ is a non-contrast, ventilation-perfusion imaging solution that provides quantitative lung function insights from routine CT scans without the need for radiotracers. The CE Mark certification is a significant milestone for 4DMedical, enabling the company to expand its market presence in Europe, which is one of the largest respiratory imaging markets globally.
Why It's Important?
The CE Mark certification for CT:VQ is crucial as it opens up the European market, which has a well-developed hospital-based imaging infrastructure and a significant number of CT scanners. This expansion is expected to address the limitations of traditional nuclear VQ scanning, such as radiotracer constraints and operational complexity. The technology's ability to integrate into existing CT workflows without requiring specialized infrastructure makes it an attractive option for healthcare providers. The adoption of CT:VQ in Europe could lead to improved diagnostic capabilities and patient outcomes in respiratory care, potentially setting a new standard in lung imaging.
What's Next?
With the CE Mark certification, 4DMedical plans to advance its commercial engagement across Europe, working with leading hospitals and clinicians to adopt and evaluate CT:VQ. The company has also secured AU$83 million in private placement funding to support its growth initiatives, including the European expansion. As the technology gains traction, it is likely to influence the adoption of advanced imaging solutions in other regions, potentially leading to further regulatory approvals and market expansions.
